Black Diamond Therapeutics Announces Restructuring Plan to Focus Resources on BDTX-1535 and Extend Cash Runway
Provided By GlobeNewswire
Last update: Oct 7, 2024
Company advancing BDTX-1535 in EGFRm NSCLC towards key inflection points in Q1 2025
Will deprioritize BDTX-4933 and seek potential partners
Read more at globenewswire.com
